Skip to main content
Clinical Trials/JPRN-UMIN000027775
JPRN-UMIN000027775CompletedPhase 2

Prospective multicenter study regarding the efficacy of Gemcitabine (gemzar) plus nab-Paclitaxel (Abraxane) regimen for locally advanced pancreatic cancer - GEAR study

Kyushu-Yamaguchi study group of therapy for pancreatobiliary cancer0 sites37 target enrollmentStarted: July 1, 2017Last updated:
Conditions

Trial Snapshot

Phase
Phase 2
Status
Completed
Sponsor
Enrollment
37

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
20years-old to 75years-old (—)
Sex
All

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1) Present or previous (within 5 years) double cancer except for carcinoma in situ 2) Pregnant females, possibly pregnant females, females feeding babies and males wishing partners' pregnancy 3) Active infection 4) Severe mental disorder 5) Interstitial pneumonia or pulmonary fibrosis 6) Severe heart disease, liver disease and uncontrolled diabetes 7) Patients positive for HBs antigen 8) Patients inadequate for enhanced CT scan 9) Severe allergy for drugs 10) Patients with inadequate condition

Investigators

Sponsor
Kyushu-Yamaguchi study group of therapy for pancreatobiliary cancer

Similar Trials